Research detection kit PC202302011

for lung cancerRET fusionRET gene

The RET proto-oncogene is located at 10q11.2 and is 60 kb , including 21 exons. After the RET gene is fused, dimerization can be completed without ligands, which will cause the RET tyrosine kinase region and downstream MAPK, PI3K/AKT and other signaling pathways continuously activated，leading to cellular proliferation, migration, and differentiation. Gain-of-function alterations in RET have been implicated in human malignancy. KIF5B is the most common RET fusion partner in NSCLC, and seven different KIF5B-RET variants have been identified RET FUSION AND TARGETED THERAPY OF LUNG CANCER In 2020, the FDA successively approved Selpercatinib and Pralsetinib for the systemic treatment of patients with RET fusion-positive metastatic non-small cell lung cancer (NSCLC). Based on the approval of the drug, the NCCN include RET fusion detection in the recommendation of NSCLC molecular detection. DETECTION SIGNIFICANCE 1. Inoperable stage III and IV NSCLC patients should be detected for RET gene fusion before systemic treatment, and treatment should be guided by molecular classification. 2. Select patients for the targeted treatment of NSCLC based on the presence of RET positivity. FEATURES & ADVANTAGES 1. Accuracy and Reliability:Use pre-load PCR tube to effectively avoid cross-contamination. 2. High Sensitivity: Sensitivity can reach as low as 100 copies in RNA. 3. Comprehensive Coverage: Covers the 7 most common KIF5B-RET variants in NSCLC. DETECTION PROCESS 1、Nucleic Acid Extraction 3、Amplification 4、Data Analysis